-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

SCI-9 Newest Discoveries Using Next Generation Sequencing Approaches for Minimal Residual Disease

Program: Scientific Program
Session: Getting the Most from Minimal Residual Disease
Sunday, December 6, 2020, 1:55 PM-2:00 PM

Ash A. Alizadeh, MD, PhD

Stanford University, Stanford, CA

Disclosures: Alizadeh: Genentech: Consultancy; Pharmacyclics: Consultancy; Chugai: Consultancy; Roche: Consultancy; Gilead: Consultancy; Celgene: Consultancy; Pfizer: Research Funding; Janssen: Consultancy.

See more of: Getting the Most from Minimal Residual Disease
See more of: Scientific Program
<< Previous Presentation | Next Presentation >>